11/10/2006 | BT | RBC puts Kos at sector perform
|
11/6/2006 | BT | RBC downgrades Kos to sector perform
|
11/6/2006 | BT | Market Commentary: Abbott Labs stock off on Kos Pharmaceuticals acquisition news; VaxGen may lose government contract
|
9/29/2006 | BT | RBC keeps Kos at outperform
|
9/22/2006 | BT | RBC maintains Kos at outperform
|
9/22/2006 | BT | Market Commentary: Amgen leads sector lower; Dyax gains on Kos' loss; Oscient rises; Gene Logic up; Discovery Labs off
|
9/21/2006 | BT | Jerini reports one phase 3 trial of Icatibant meets goal, one does not
|
9/18/2006 | BT | Kos Pharmaceuticals regains Nasdaq listing compliance
|
9/6/2006 | BT | SkyePharma, Mundipharma to market Flutiform for asthma in Europe
|
8/16/2006 | BT | Kos faces possible Nasdaq delisting
|
8/11/2006 | BT | Market Commentary: Encysive spikes, slips to red; SkyePharma still looking for buyer; Pharmacyclics sinks
|
8/9/2006 | BT | RBC maintains Kos at outperform
|
8/8/2006 | BT | Kos says NDAs for Icatibant, Flutiform to be filed by year-end, reports $13.9 million Q2 net income
|
7/25/2006 | BT | Kos: Aspirin reduces 'flushing' for patients taking cholesterol drug Niaspan
|
7/12/2006 | BT | Kos submits supplemental New Drug Application for new Niaspan CF product
|
6/20/2006 | BT | Kos says Niaspan improves lipid control
|
5/9/2006 | BT | Kos to buy back up to 7 million shares to offset stock compensation costs, return value
|
5/8/2006 | BT | SkyePharma, Kos sign deal for marketing, distribution of asthma drug Flutiform in United States
|
4/24/2006 | BT | Jerini completes randomization in phase 3 clinical trial of Icatibant for hereditary angioedema
|
4/12/2006 | BT | Market Commentary: Vanda, Targacept tank on debut; Omrix IPO in limbo; Novavax, KOS climb; Discovery soars after hours
|
3/10/2006 | BT | Market Commentary: Insmed, Corautus off on deals; NPS Pharma gains, dives on FDA; CV Therapeutics higher; Kos up
|
2/24/2006 | BT | Kos at hold/high risk by Citigroup
|
2/23/2006 | BT | Kos reports summary results of phase 4 studies of Niaspan
|
2/23/2006 | BT | Market Commentary: Kos crashes on results, warning; GTC garroted by E.U. rejection; Nastech higher; Biovail mixed
|
2/22/2006 | BT | Citigroup reiterates KOS at hold
|
12/16/2005 | BT | Kos reiterated by Citigroup at hold
|
12/16/2005 | BT | Market Commentary: Amgen, Abgenix easier; takeover talk fuels rise in Imclone, several other biotechs; Kos slide continues
|
11/16/2005 | BT | Kos' Niaspan/statin combination causes regression of atherosclerosis, study says
|
11/14/2005 | BT | Kos preclinical study shows Reverse-D4F may reduce the progression of atherosclerosis
|
11/8/2005 | BT | Kos Life Sciences and Jerini US form development and marketing agreement for Icatibant
|